<DOC>
	<DOC>NCT00849355</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy (and safety) of the following treatment squeme:Ciclophosphamide, Vincristine, lyposomal Doxorrubicine (Myocet) and Prednisone,combined with Rituximab in first line treatment for patients with aggresive No Hodgkin B lymphoma and cardiovascular risk</brief_summary>
	<brief_title>Ciclophosphamide, Vincristine, Myocet and Prednisone, With Rituximab in 1st-Line Treatment for Patients With No-Hodgkin B Lymphoma and Cardiovascular (CV) Risk</brief_title>
	<detailed_description>Phase II, multicenter, open , 1-arm study.</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>1. Patients with histological diagnosis of Lymphoma no Hodgkin B CD20+ high degree of mailgnancy 2. Patients no previously treated 3. stage III o IV 4. Informed consent 5. At least one measurable injury 6. Age &gt;18 7. ECOG 02 8. Life expectancy &gt;6 months 9. Cardiovascular risk defined as:Mildmoderate systolic dysfunction,isquemic cardiopathy, diabetes mellitus, hypertension,left ventricular hypertrophy, cardiac arrhythmia, moderate pulmonar hypertension 10. adequate organic functionallity (creatinine&lt;2mg/dl;bilirubin&lt;2mg/dl; ALTASTFA&lt;5 FSN; neutrphyls total count &gt;1.5x 109/l and platellet count &gt;100x1097l) 11. Use of a contraceptive method during study + 3 months 1. stage I or II with IPI=0 2. Symptomatic tumoral affection of Nervous central system 3. Lymphoma no hodgkin B indolent 4. Lymphoma no hodgkin B mantlecell 5. Lymphoma no hodgkin T 6. lymphoprolifertaive syndrome posttransplantation or immunosuppression associated 7. cardiovacualr disease symptomatic 8. Cronic infection or acute serious 9. history of neoplasia in past 5 years 10. not able to understand the study or poor protocol adherence 11. Known Hypersensivity to any atudy drug 12. pregnant/lactant women 13. Previous participation in clinicla study in past 30 days 14. Previous treatment with antraciclines or any drug used in this study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2009</verification_date>
</DOC>